Catch-up growth after dexamethasone withdrawal occurs in cultured postnatal rat metatarsal bones

Andrei S Chagin, Elham Karimian, Katja Sundström, Emma Eriksson and Lars Sävendahl

Pediatric Endocrinology Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm SE-17176, Sweden

(Correspondence should be addressed to A S Chagin who is now at Endocrine Unit, Thier 1101, Massachusetts General Hospital, 50 Blossom Street, Boston, Massachusetts 02114, USA; Email: achagin@partners.org)

Abstract

Children exposed to systemic glucocorticoids often exhibit growth retardation and after the cessation of therapy catch-up growth occurs in many, but not all patients. The developmental regulation and underlying cellular mechanisms of catch-up growth are not fully understood. To clarify this issue, we established an in vitro model of catch-up growth. Here we present a protocol for the long-term culture (up to 160 days) of fetal (E20) as well as postnatal (P8) rat metatarsal bones which allowed us to characterize ex vivo the phenomenon of catch-up growth without any influence by systemic factors. The relevance of the model was confirmed by the demonstration that the growth of fetal and postnatal bones were stimulated by IGF1 (100 ng/ml) and inhibited by dexamethasone (Dexa; 1 μM). We found that the capacity to undergo catch-up growth was restricted to postnatal bones. Catch-up growth occurred after postnatal bones had been exposed to Dexa for 7 or 12 days but not after a more prolonged exposure (19 days). Incomplete catch-up growth resulted in compromised bone length when assessed at the end of the 4-month period of culture. While exposure to Dexa was associated with decreased chondrocyte proliferation and differentiation, catch-up growth was only associated with increased cell proliferation. We conclude that the phenomenon of catch-up growth after Dexa treatment is intrinsic to the growth plate and primarily mediated by an upregulation of chondrocyte proliferation.

Journal of Endocrinology (2010) 204, 21–29

Introduction

Longitudinal bone growth occurs at the growth plate by a process called endochondral ossification where a continuously formed cartilage template is substituted by newly formed bone tissue (Kronenberg 2003, Chagin & Sävendahl 2007). Dexamethasone (Dexa) is a well-known inhibitor of longitudinal bone growth. It exerts growth-inhibiting effects both systemically through downregulation of the GH/insulin-like growth factor 1 (IGF1) axis, and directly through inhibition of chondrocyte proliferation, mineralization, and increased apoptosis (van der Eerden et al. 2003, Mushtaq et al. 2004, Nilsson et al. 2005). The direct effects of Dexa are believed to be partly caused by downregulation of the GH receptor and/or the IGF1 receptor at the growth plate level (van der Eerden et al. 2003, Nilsson et al. 2005).

Catch-up growth after glucocorticoid exposure is a less understood phenomenon where growth velocity rises above the corresponding control after cessation of treatment (Boersma & Wit 1997). Catch-up growth was first proposed to occur via a neuroendocrine mechanism where an organism recognizes the degree of mismatch between its target size and its actual size, and consequently adjusts growth rate according to the degree of mismatch (Tanner 1963). Later this hypothesis was challenged by experiments where partial catch-up growth of one leg was observed after local infusion of Dexa into the rabbit growth plate (Baron et al. 1992, 1994a). This observation gave rise to the senescence hypothesis which proposes that glucocorticoids delay senescence of chondrocytes, where senescence is a function of cell division and delayed chondrocyte proliferation preserves the proliferative capacity. Therefore, after cessation of treatment, chondrocytes proliferate like younger cells demonstrating increased growth velocity compared with controls (Baron et al. 1994a). However, the extent to which local and systemic mechanisms contribute to the phenomenon of catch-up growth is still unclear.

In the present work, we characterized an in vitro model that mimics the clinically observed catch-up growth after cessation of glucocorticoid exposure. For this purpose, we optimized a well-known model of fetal rat metatarsal bone culture (Scheven & Hamilton 1991, Mancilla et al. 1998, De Luca et al. 2001, Martensson et al. 2004) and characterized the growth pattern of postnatal metatarsal bones, which have not previously been successfully grown ex vivo (Scheven & Hamilton 1991, Coxam et al. 1996). Our results demonstrate that the catch-up growth is specific to the postnatal growth plate and is attributed to local mechanisms. Moreover, catch-up growth is clearly associated with increased chondrocyte proliferation.
Materials and Methods

Materials

IGF1, Dexa, BSA, and β-glycerophosphate were all purchased from Sigma–Aldrich, Inc. PBS, DMEM/F12, MEM, fetal bovine serum, and gentamycin were all purchased from Invitrogen, Inc. Ascorbic acid was purchased from ICN Corp. (Aurora, OH, USA).

Bone culture

The hindpaws of Sprague–Dawley rat fetuses at day 20 of gestation (E20) or from Sprague–Dawley rats at day 8 of age were collected in DMEM/F12 supplemented with 20 μg/ml gentamycin on ice. The three middle metatarsal bones were microdissected and then cultured in 24-well plates in either MEM or DMEM/F12 medium changed every 2–3 days. Both culture media were supplemented with 1 mM β-glycerophosphate, 50 μg/ml ascorbic acid, 0.2% BSA, and 20 μg/ml gentamycin. These experiments were pre-approved by the Local Ethics Committee at Karolinska Institutet, Stockholm, Sweden.

Length measurements

Digital images of cultured bones were captured at days 0, 2, 5, 7, 12, 19, and 26 and thereafter once a week using a stereo microscope (Nikon SMZ-U) connected to a digital camera (Hamamatsu C4742–95) and a computer. Images were analyzed as previously described (Martensson et al. 2004) using the Image-ProPlus image analysis software (Media Cybernetic, Gleichen, Germany) by a person blinded to the nature of the treatment groups. Bone lengths were expressed in millimeters. For a given time point, growth velocity was calculated by dividing the increase in bone length since the previous measurement with the time interval between the two measurements.

BrdU incorporation

For BrdU labeling, 2-5 h (or 24 h) prior to fixation, rat metatarsal bones were washed once in PBS and the DMEM/F12 medium was changed to MEM medium supplemented with BrdU labeling reagent (1:200 dilution of labeling reagent, Cell Proliferation Kit RPN20, Amersham Biosciences). BrdU detection and quantification were performed as previously described (Chagin et al. 2007).

Terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP nick end labeling

Apoptotic cells were identified by terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP nick end labeling (TUNEL) in situ using the TdT-FragEL DNA fragmentation kit according to the manufacturer’s instructions (Oncogene Research, Boston, MA, USA). The following modifications were previously introduced: sections were treated with 5 μg/ml proteinase K for 10 min (Martensson et al. 2004). DNA incorporation of biotin-labeling nucleotides was detected by streptavidin conjugated to Alexa Fluor 546 (Invitrogen Inc.), and slides were embedded in DAPI-containing mounting medium (Vector Laboratories Inc., Burlingame, CA, USA). The level of apoptosis was calculated as the percentage Alexa-546 positive cells of DAPI positive cells (total cell number) employing the Image-ProPlus image analysis software (Media Cybernetic) as previously described (Chagin et al. 2007). Distilled water was used instead of TdT as a negative control for cell labeling.

Quantitative histology

Four micrometer sections of the metatarsal bones were counterstained with Alcian blue/van Gieson or hematoxylin/eosin. Distal growth plates were exclusively used for histological analysis. The proliferative zone was defined as the layer with columnar appearance between rounded chondrocytes in the resting and hypertropic zones. The heights of both proliferative and hypertropic zones were calculated as an average of 10 measurements per bone. Hypertropic chondrocytes were defined by a height of more than 7 μm (Tivesten et al. 2004). The size of hypertropic chondrocytes was averaged by measuring 25 hypertropic chondrocytes per distal growth plate in the hypertropic zone between the third and seventh cell layers (counted from the metaphyseal side; Chagin et al. 2009). Measurements were performed using the Image-ProPlus image analysis software (Media Cybernetic). All histological measurements were made by a single person unaware about the origin of the images.

Immunohistochemistry

Rat metatarsal bones were fixed in 4% formaldehyde, paraffin embedded and 4 μm-thick sections were obtained. Immunohistochemistry was performed as described elsewhere (Nilsson et al. 2002). The primary rabbit polyclonal anti-IGF1 (H-70) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and used at a dilution of 1:100 (Chagin et al. 2006, Shao et al. 2007). Secondary polyclonal goat anti-rabbit biotinylated antibody was purchased from DakoCytomation A/S (Glostrup, Denmark) and applied in a 1:400 dilution. For detection of collagen type X, antigen retrieval was performed in citrate buffer at 95 °C for 15 min followed by peroxidase quench in 3% H2O2 for 10 min. Sections were subsequently treated with 5 mg/ml hyaluronidase (Sigma–Aldrich, Inc.) for 30 min at 37 °C. Anti-collagen type X antibody (Quartett GmbH, Berlin, Germany) was used at a dilution of 1:30 overnight.

Journal of Endocrinology (2010) 204, 21–29
Statistical analysis

Statistical differences were calculated by one-way ANOVA followed by the Holm–Sidak test if more than two groups were compared. The unpaired Student’s t-test was used to calculate statistical differences between two groups (Fig. 1). For determination of growth pattern three to four bones were used per treatment group for every experiment and every experiment was repeated at least three times. For determination of proliferation, apoptosis or cell morphometry four to five bones were analyzed for every treatment or time-point.

Results

Establishment of long-term cultures of fetal and postnatal rat metatarsal bones

Based on our previous studies on short-term cultures of fetal rat metatarsal bones, we believe that bones cultured in DMEM/F12 medium (Chagin et al. 2006, 2007, Heino et al. 2008) grow better than those cultured in MEM (Mancilla et al. 1998, Martensson et al. 2004, Zaman et al. 2007) or alpha MEM (Chagin et al. 2009) media. However, a direct formal comparison has never been made before. To facilitate the establishment of long-term metatarsal bone cultures, we first compared the growth of fetal metatarsal bones when cultured in either MEM or DMEM/F12 medium. Already after 2 days in culture, bone growth and chondrocyte proliferation rate were significantly higher in those bones cultured in DMEM/F12 medium (P < 0.001 versus MEM, Fig. 1A and B). Furthermore, a central depletion of chondrocytes was observed in a majority of bones cultured for more than 2 weeks in MEM medium (Fig. 1C), a phenomenon which was never observed when cultured in DMEM/F12 medium (Fig. 1D). When cultured in DMEM/F12 medium, fetal (E20) rat metatarsal bones continued to grow throughout the 3-month observation period (Fig. 2A and B) although the growth velocity gradually declined over time (Fig. 2C). The significant improvement of fetal bone growth linked to the introduction of the more enriched DMEM/F12 medium enabled us to expand our in vitro studies, also including cultures of postnatal metatarsal bones dissected between 5-day and 8-day (P8) old rats as well as from 4-day-old mice (Fig. 2 and data not shown for bones dissected from 5-day old rats and 4-day-old mice). When comparing E20 and P8 bones, we found that the growth velocities were comparable throughout the 3-month period of culture with the exception of a more rapid initial decline in the growth of P8 bones (Fig. 2C) which was accompanied by a parallel decline in chondrocyte proliferation rate (Fig. 2D). All columnar chondrocytes turn into hypertropic cells somewhere after 70–90 days in culture and, therefore, essentially no BrdU incorporation (24 h labeling) was observed after this time point (Fig. 2D and data not shown). Bone growth was primarily attributed to growth of the cartilage template while the length of the diaphysis did not significantly change and no secondary ossification center was formed (Supplementary Figure 1, see section on supplementary data given at the end of this article). Thus, there was no bone tissue formation.
ex vivo despite formation of a cartilage template, presumably due to the lack of blood supply. These observations also indicate that bone maturation does not occur in the ex vivo setting.

Responsiveness to IGF1 in cultured fetal and postnatal rat metatarsal bones

IGF1 (100 ng/ml) stimulated the growth of fetal (E20) and postnatal (P8) metatarsal bones in a similar way (Fig. 3A and B). After 2 days of IGF1 exposure, the lengths of E20 and P8 bones exceeded that of control bones by 84±6 and 83±8% respectively (P<0.001 versus control). Similarly, when assessed over the first 2 days of exposure, the growth velocities of IGF1 treated bones were identical in the E20 and P8 groups (364±37 and 367±15 μm/day respectively; Fig. 3C and D). Interestingly, IGF1 promoted only a transient increase in growth velocity. Moreover, growth velocity declined more rapidly in bones isolated from older rats (P8) reaching control values after 5 days while in E20 bones it returned to the control level first after 12 days (Fig. 3C and D). Between days 2 and 5 of culture, a transient drop in growth velocity was recorded in E20 bones (Fig. 3C). However, this we believe is an artifact caused by the early disappearance of loose connective tissue that remained after the microdissection of these small bones. Interestingly, IGF1 was capable of stimulating postnatal metatarsal bone growth even when added after 75 days in culture suggesting an intact IGF-responsiveness throughout these long-term cultures (Fig. 3B and D).

Dexa inhibits growth of both fetal and postnatal rat metatarsal bones in culture

Treatment with Dexa (1 μM) for 12 days inhibited the growth of both fetal (E20; Fig. 4A) and postnatal (P8; Fig. 4B) metatarsal bones in culture. Interestingly, P8 bones were more sensitive to Dexa-induced growth retardation than E20 bones. When assessed after 7 days exposure to Dexa, growth velocity was 55±17 and 8±4 μm/day in E20 and P8 bones respectively (Fig. 4C and D).

Catch-up growth after Dexa-treatment occurs in postnatal but not in fetal bones

After discontinuing Dexa treatment on day 12, a clear catch-up growth (defined as a time period with growth velocity significantly above the corresponding control) was observed in P8 bones peaking on day 26 (growth velocity 82±8 vs 52±5 μm/day in control, P<0.001, Fig. 4D). The difference in length between control and Dexa-treated P8 bones decreased with time; from 1105±40 μm at day 12 to 593±134 μm at day 110 of culture (P<0.001). In contrast, after cessation of Dexa treatment in E20 bones, growth...
velocity only reached the control level and consequently no catch-up growth occurred (Fig. 4A and C). The difference in bone length between control and Dexa-treated E20 bones further increased with time in culture; from 951±39 μm at day 12 to 1587±134 μm at day 110 (P<0.001). Altogether, these data demonstrate that catch-up growth after Dexa treatment occurs in postnatal but not in fetal metatarsal bones.

Catch-up growth is dependent on the duration of previous Dexa exposure

To clarify if the capacity for catch-up growth is dependent on the duration of previous glucocorticoid exposure, P8 bones were divided into the following groups: control (treatment with vehicle (0.1% EtOH) for 12 days, thereafter culture medium); Dexa7 (treatment with Dexa for 7 days, thereafter culture medium); Dexa12 (treatment with Dexa for 12 days, thereafter culture medium); and Dexa19 (treatment with Dexa for 19 days, thereafter culture medium). These bones were monitored throughout a 160-day period of culture. After discontinuing Dexa treatment, a clear catch-up growth was observed in Dexa7 (84±4 vs 52±5 μm/day in control; day 19; P<0.001) and Dexa12 (82±8 vs 52±5 μm/day in control; day 26; P<0.001) but not in Dexa19 bones (Fig. 5A). After 120 days in culture, Dexa7 bones had reached the same length as control bones (9.3±0.2 vs 9.5±0.2 mm for control; P>0.05) while Dexa19 bones were significantly shorter still after 160 days in culture (9.1±0.1 vs 9.9±0.2 mm for control; P<0.001) (Fig. 5B) albeit the length difference between treated and untreated bones decreased with time (1657±71 μm for day 26 versus 770±186 μm for day 160; P<0.001). Dexa12 bones exhibited an intermediate growth pattern compared to Dexa7 and Dexa19 bones and the length at day 160 of culture was not statistically different from control bones (9.5±0.3 vs 9.9±0.2 mm; P>0.05) (Fig. 5B). Remarkably, all bones were still growing after 160 days of culture although the growth velocity was quite low at that time point (4.3±1.4 μm/day for control; 6.8±1.7 μm/day for Dexa7, 7.9±2.3 μm/day for Dexa12; and 4.9±1.1 μm/day for Dexa19; Fig. 5A).

Cellular mechanisms of catch-up growth in cultured postnatal metatarsal bones

Treatment of P8 bones with Dexa for 7 or 19 days clearly inhibited chondrocyte proliferation when assessed on the last day of exposure (P<0.01 versus control; Fig. 6A). When assessed 5 days after the cessation of 7 days Dexa treatment (Day 7+5), chondrocyte proliferation rate was significantly elevated when compared with corresponding control bones (P<0.001; Fig. 6A). In contrast, the proliferation rate had not increased when determined 5 days after the termination of 19 days of previous exposure to Dexa (Day 19+5; Fig. 6A). These findings are in line with the observed catch-up growth in P8 bones exposed to Dexa for 7, but not 19 days (Fig. 5A).

Morphological analysis of the height of the proliferative zone did not reveal any differences between the groups (Fig. 6B and Supplementary Figure 2, see section on supplementary data given at the end of this article). Together with decreased proliferation, this observation suggests that Dexa delayed the chondrocyte transition from flat towards hypertropic chondrocytes and thereby suppressed growth. In support of this observation, the number of hypertropic chondrocytes was decreased in Dexa-treated bones (Fig. 6F). Moreover, Dexamethasone suppressed chondrocyte hypertrophy as determined by collagen type X immunostaining (Fig. 6C), hypertropic zone length (Fig. 6D) and hypertropic chondrocytes size (Fig. 6E). In contrast to proliferation rate, none of the hypertrophy parameters did undergo catch-up after the cessation of Dexa treatment (Fig. 6C–E).
As IGF1 is known to stimulate chondrocyte hypertrophy, we examined whether the expression of this protein was affected during and after the exposure to Dexa. Indeed, the expression level of IGF1 was reduced by Dexa as early as after 7 days of treatment ($P < 0.001$) but was not restored 5 days after the cessation of the exposure (Supplementary Figure 3, see section on supplementary data given at the end of this article), suggesting that regulation of IGF1 expression by Dexa is not involved in the observed catch-up growth.

As glucocorticoid exposure in vivo has been linked to increased chondrocyte apoptosis in the rat growth plate (Chrysis et al. 2003), we also performed TUNEL-analysis in postnatal (P8) rat metatarsal bones exposed to Dexa ex vivo. We then observed that the level of apoptosis (TUNEL-positive cells) was increased by $18 \pm 55\%$ at day 7 of continuous Dexa exposure and by $134 \pm 50\%$ at day 19 of continuous Dexa exposure ($P = 0.9$ and $P = 0.069$ versus control respectively). Albeit not statistically significant, these data suggest that apoptosis may be a cause of compromised growth after prolonged exposure to Dexa.

**Discussion**

Here we present a new protocol allowing long-term studies of fetal as well as postnatal rat metatarsal bone growth ex vivo. The strengths of the model include persistent growth over at least 5 months in culture under serum-free conditions, an ability to respond to known suppressors and stimulators of bone growth,

---

and importantly a possibility to study the phenomenon of catch-up growth in *ex vivo*. Applying this model, we found that the capacity for catch-up growth after cessation of glucocorticoid exposure is restricted to postnatal bones and negatively correlated to the duration of treatment with Dexa.

We found that both fetal and postnatal rat metatarsal bones have the capacity to grow for up to 5 months *ex vivo* when cultured in a medium free from serum but rich in nutrients (DMEM/F12). It has generally been postulated that postnatal bones do not grow *ex vivo* (Scheven & Hamilton 1991, Coxam *et al*. 1996). Postnatal bones cultured in MEM supplemented with 1% BSA have been reported to grow negligibly when compared to fetal bones (Coxam *et al*. 1996).

To our knowledge, so far there is only one recent report of a successful short-term culture of postnatal bones demonstrating that metatarsals from 2-day-old mice can be grown for 8 days in the presence of 10% bovine serum (MacRae *et al*. 2006). When comparing the growth patterns of fetal and postnatal bones, we found that after being transferred to *ex vivo* conditions, growth velocity decreased earlier in postnatal bones, which may be linked to the fact that they are older. The observed decline in growth velocity was associated with a gradual decrease in chondrocyte proliferation. This is in line with the senescence hypothesis proposing that chondrocyte senescence is a function of their proliferative capacity (Baron *et al*. 1994a). Interestingly, metatarsal bone growth velocity never reached zero, not even after 5 months in culture, which most likely reflects the fact that rodent bones continue to grow even later in life, although at a slow rate.

Here we report that both fetal and postnatal metatarsal bones cultured *ex vivo* have the capacity to respond to Dexa and IGF1, a known suppressor and stimulator of bone growth respectively (van der Eerden *et al*. 2003, Mushtaq *et al*. 2004). We found that IGF1 stimulated the growth of fetal and postnatal bones in a similar way. To our surprise, after 75 days in culture, postnatal bones still had an intact IGF1 responsiveness which strengthens the relevance of this model for long-term mechanistic studies of the regulation of postnatal bone growth. Furthermore, this observation suggests that growth plate chondrocytes are not going through dedifferentiation when cultured under these conditions. When exposed to Dexa, growth velocity almost approached zero in postnatal bones while it was partially preserved in fetal metatarsals suggesting that postnatal growth is more sensitive to Dexa exposure than fetal. In contrast, postnatal bone growth demonstrated a better ability to recover compared to fetal bones. Altogether, our data demonstrate that postnatal bones exhibit a similar growth pattern as fetal bones and respond to hormonal stimuli as expected when kept in long-term cultures *ex vivo*.

The new protocol launched here allows bones to be cultured *ex vivo* for prolonged periods of time, thereby allowing mechanistic studies of the phenomenon of catch-up growth. Here we decided to focus on Dexa-induced growth retardation since the capacity for catch-up growth after glucocorticoid exposure is of great clinical relevance. Our *ex vivo* finding that catch-up growth occurs after short-term (7 and 12 days) but not long-term (19 days) Dexa exposure mimics what occurs in children known to display catch-up growth after previous short-term glucocorticoid exposure while prolonged exposure results in incomplete catch-up growth and compromised final height (Mosier *et al*. 1972, Strickland *et al*. 1972). Mechanistic studies, showed that upon cessation of Dexa treatment, the level of chondrocyte proliferation rose above control after short-term exposure (7 days) but not long-term (19 days) exposure, whereas differentiation was unchanged in both cases, suggesting that increased proliferation most likely is the primary local underlying mechanism for the phenomenon of catch-up growth. Interestingly, the duration of Dexa exposure was positively correlated to the time period needed for growth to normalize since after prolonged exposure to Dexa (19 days), growth velocity reached control level first 10 days after the cessation of treatment while after short-term exposure (5 days) growth velocity normalized earlier. Accordingly, normalization of cell proliferation in 19 days Dexa-exposed bones was not observed 5 days after cessation of treatment in contrast to bones exposed only for 7 days. Our *ex vivo* data are in line with the previously published *in vivo* observation that growth plate chondrocyte proliferation rate is increased upon cessation of systemic glucocorticoid treatment (Gafni *et al*. 2001), previous tamoxifen treatment (Karimian *et al*. 2008) and hypothyroidism (Marino *et al*. 2008). To our knowledge, it has previously not been demonstrated that elevated proliferation during catch-up growth is attributed to local mechanisms within the growth plate. Previous reports shows increased apoptosis in growth plate chondrocytes after high-dose Dexa treatment in rats *in vivo* (Chrysis *et al*. 2003) and in cultured human chondrocytes (Chrysis *et al*. 2005) suggesting that apoptosis may contribute to incomplete catch-up growth after glucocorticoid exposure. Such a mechanism is supported by our present observation of a slight increase in the level of chondrocyte apoptosis after long-term Dexa exposure, although the differences did not reach statistical significance.

It has previously been suggested that glucocorticoid effects on bone growth may be mediated through modulation of IGF1 (van der Eerden *et al*. 2003), a growth factor known to stimulate proliferation and hypertrophy while suppressing apoptosis in growth plate chondrocytes (Chrysis *et al*. 2005). Here we report that Dexa treatment reduced the proportion of growth plate chondrocytes expressing IGF1 and that the expression level remained below control even after cessation of the treatment when catch-up growth occurred. Together with previous findings (Luo & Murphy 1989, Wang *et al*. 1999), our data support a role for IGF1 as a mediator of Dexa-induced growth retardation but not in the subsequent process of catch-up growth. Furthermore, the observation that catch-up growth may occur under serum-free conditions indirectly suggests that catch-up growth is not dependent on systemic factors.
The fact that catch-up growth after Dexa-exposure occurred \textit{ex vivo} in cultured postnatal bones strongly suggests that the phenomenon of catch-up growth must, at least partially, be intrinsic to the growth plate. This conclusion is supported by previously published \textit{in vivo} data showing that unilateral injection of Dexa into the rabbit tibia growth plate resulted in unilateral growth restriction followed by partial restoration of bone length upon cessation of the treatment \cite{baron1992,baron1994a}. Despite support from previous observations \cite{baron1994a,baron1994b}, we cannot exclude the involvement of systemic mechanisms in the catch-up phenomenon since not only bones display catch-up growth, but also the entire organism \cite{tanner1963}.

We observed that after Dexa treatment, catch-up growth occurs in postnatal but not in fetal bones. In some studies, treatment of premature infants with Dexa was associated with decreased longitudinal growth \cite{wood2007}, but this was not confirmed by others \cite{halliday2001,romagnoli2002}. Interestingly, premature infants with a relative insensitivity to glucocorticoids, exhibit a complete catch-up growth during the first 2 years of life while infants without this polymorphism remain below the mean height for the normal population up to 19 years of age \cite{finken2007}. This finding is in line with our \textit{in vitro} observation of an absent catch-up growth in fetal bones after the exposure to Dexa. However, rats prenatally exposed to Dexa indeed have been reported to undergo postnatal catch-up growth \cite{o'regan2004} emphasizing the need for further studies clarifying catch-up growth after exposure to glucocorticoids during fetal life.

In summary, here we present a protocol for the long-term culture of fetal as well as postnatal rat metatarsal bones which allowed us to confirm that catch-up growth may occur \textit{ex vivo} without any influence of systemic factors. We also found that the capacity for catch-up growth after cessation of Dexa exposure is restricted to postnatal bones and negatively correlated to the duration of the treatment. Finally, our data link catch-up growth to increased chondrocyte proliferation rate which most likely is the major local underlying mechanism for this phenomenon.

### Supplementary data

This is linked to the online version of the paper at http://dx.doi.org/10.1677/JOE-09-0307.

### Declaration of interest

We declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

### Funding

This study was funded by the Swedish Research Council, Sälgkapet Barnavård, Stiftelsen Frimurare Barnhuset i Stockholm and HKH Kronprinsessan Lovisas förening för Barnsjukvård.

### References


Chrysis D, Ratzen EM & Savendahl L 2003 Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. \textit{Journal of Endocrinology} \textbf{176} 331–337.


www.endocrinology-journals.org


Received in final form 6 October 2009
Accepted 8 October 2009
Made available online as an Accepted Preprint 8 October 2009